卡巴拉汀（艾斯能）用于帕金森病患者的痴呆治疗。
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
作者信息
Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn A D
机构信息
Department of Neurology, Tel-Aviv Sourasky Medical Center, Israel.
出版信息
Acta Neurol Scand. 2003 Nov;108(5):368-73. doi: 10.1034/j.1600-0404.2003.00211.x.
OBJECTIVES
To study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease (PD).
METHODS
We treated twenty-eight demented patients with PD openly for 26 weeks with rivastigmine (mean daily dose 7.2 +/- 3.3 mg/day). Baseline scores were compared with those at weeks 12, 26 and after 8 weeks of washout.
RESULTS
Twenty patients completed 26 weeks of treatment and eight dropped out because of side effects. The Unified Parkinson's Disease Rating Scale mental subscore improved significantly at week 26 (P < 0.01) while the motor score (part III) did not change. The mean ADAScog total score improved by 7.3 points at week 26 (P < 0.002). The subscores for recognition, word finding, remembering instructions and concentration items of the ADAScog improved significantly as well (P < 0.02, P < 0.05, P < 0.005 and P < 0.003, respectively).
CONCLUSIONS
Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function.
目的
研究胆碱酯酶抑制剂治疗帕金森病（PD）患者痴呆的疗效。
方法
我们对28例痴呆的PD患者进行了26周的开放性卡巴拉汀治疗（平均日剂量7.2±3.3毫克/天）。将基线评分与第12周、第26周以及洗脱8周后的评分进行比较。
结果
20例患者完成了26周的治疗，8例因副作用退出。统一帕金森病评定量表精神亚评分在第26周时显著改善（P<0.01），而运动评分（第三部分）未改变。第26周时，阿尔茨海默病评估量表认知总分平均提高7.3分（P<0.002）。阿尔茨海默病评估量表的识别、找词、记忆指令和注意力项目的亚评分也显著改善（分别为P<0.02、P<0.05、P<0.005和P<0.003）。
结论
卡巴拉汀可能改善PD痴呆患者的认知功能，且不会使运动功能恶化。
Zotero 插件